Clinical Trials · NCT03632759
Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D
- Phase
- EARLY_Phase 1
- Recruitment status
- Completed
- Sponsor
- Carla Greenbaum, MD
- Enrollment
- 16
- Start date
- Aug 2018
- Locations
- 2 sites, United States
- Primary endpoint
- Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL.